Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

Abstract:

:Microtubule stabilization by chemotherapy is a powerful weapon in the war against cancer. Disruption of the mitotic spindle activates a number of signaling pathways, with consequences that may protect the cell or lead to its death via apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has been utilized successfully in the treatment of solid tumors for two decades. Several features, however, make this drug less than ideal, and the search for next generation stabilizing drugs with increased efficacy has been intense and fruitful. Microtubule stabilizing agents (MSAs), including the taxanes, the epothilones, discodermolide, laulimalide, and eleutherobin, form an important and expanding family of chemotherapeutic agents. A strong understanding of their molecular signaling consequences is essential to their value, particularly in regard to their potential for combinatorial chemotherapy - the use of multiple agents to enhance the efficacy of cancer treatment. Here we present a critical review of research on the signaling mechanisms induced by MSAs, their relevance to apoptosis, and their potential for exploitation by combinatorial therapy.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Bergstralh DT,Ting JP

doi

10.1016/j.ctrv.2006.01.004

keywords:

subject

Has Abstract

pub_date

2006-05-01 00:00:00

pages

166-79

issue

3

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(06)00011-9

journal_volume

32

pub_type

杂志文章,评审
  • Finding the right dose of fulvestrant in breast cancer.

    abstract::Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may b...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.06.003

    authors: Estévez L,Alvarez I,Tusquets I,Seguí MA,Muñoz M,Fernández Y,Lluch A

    更新日期:2013-04-01 00:00:00

  • Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.

    abstract:BACKGROUND:Radical cystectomy (RC) associated with pelvic lymph node dissection (PLND) is the most common local therapy in the management of non-metastatic muscle invasive bladder cancer (MIBC). Loco-regional recurrence (LRR), however, remains a common and important therapeutic challenge associated with poor oncologic ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.07.011

    authors: Sargos P,Baumann BC,Eapen L,Christodouleas J,Bahl A,Murthy V,Efstathiou J,Fonteyne V,Ballas L,Zaghloul M,Roubaud G,Orré M,Larré S

    更新日期:2018-11-01 00:00:00

  • Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.

    abstract::Given its role in cellular metabolism, the proteasome could prove to be a critical target that can be exploited in treating cancer. In preclinical studies, several mechanisms for bortezomib's activity in multiple myeloma cells have been identified (e.g., NF-kappaB inhibition); antitumor activity with bortezomib has be...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00079-3

    authors: Cusack JC

    更新日期:2003-05-01 00:00:00

  • Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

    abstract::Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. Howe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.06.008

    authors: Bahl A,Masson S,Birtle A,Chowdhury S,de Bono J

    更新日期:2014-02-01 00:00:00

  • Markers of bone turnover in prostate cancer.

    abstract::Prostate cancer is the most common malignancy in elderly men and is often associated with bone metastases. Although bone metastases are osteosclerotic, histological and biochemical studies clearly indicate an increase of both bone formation and bone resorption, providing the rational for using bisphosphonate as a pall...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2000.0213

    authors: Garnero P

    更新日期:2001-06-01 00:00:00

  • Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

    abstract::Bladder cancer is one of the leading causes of death in Europe and the United States. About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy. In the setting of metastatic disease, use of cisplatin-based regime...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.09.018

    authors: Morales-Barrera R,Suárez C,de Castro AM,Racca F,Valverde C,Maldonado X,Bastaros JM,Morote J,Carles J

    更新日期:2016-11-01 00:00:00

  • Cardiovascular effects of breast cancer radiotherapy.

    abstract::Cardiac toxicity has been implicated as the primary reason for excess non-breast cancer mortality in early breast cancer radiotherapy studies. Refinements in radiotherapy techniques have allowed for a considerable reduction of this risk in the majority of breast cancer patients. Recent large population-based studies c...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.07.011

    authors: Senkus-Konefka E,Jassem J

    更新日期:2007-10-01 00:00:00

  • Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.

    abstract::Since its first regulatory approval more than 10 years ago, oncologists have gained wide experience in using the oral fluoropyrimidine, capecitabine, as monotherapy or in combination with other agents and the body of evidence supporting these approaches continues to grow. Alongside this increasing experience has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.06.003

    authors: Barrett-Lee P,Bidard FC,Pierga JY

    更新日期:2009-11-01 00:00:00

  • Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding?

    abstract::An increasing number of women are diagnosed with cancer during pregnancy and lactation. Women are usually advised to interrupt breastfeeding during systemic anticancer treatment for fear of serious adverse effects to the nursed infant. However, the issue is poorly addressed in the literature and very few studies have ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.10.002

    authors: Pistilli B,Bellettini G,Giovannetti E,Codacci-Pisanelli G,Azim HA Jr,Benedetti G,Sarno MA,Peccatori FA

    更新日期:2013-05-01 00:00:00

  • Fertility preservation in cancer patients: the global framework.

    abstract::Cancer treatment is the most frequent cause of reduced fertility in cancer patients, with up to 80% of survivors affected. None of the established or experimental fertility preservation methods can assure parenthood, rather they may provide a future opportunity to overcome treatment induced sterility. Around 70-75% of...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.06.001

    authors: Linkeviciute A,Boniolo G,Chiavari L,Peccatori FA

    更新日期:2014-09-01 00:00:00

  • A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumour aggressiveness in pelvic cancer.

    abstract::Diffusion-weighted magnetic resonance imaging (DW-MRI) is used extensively to improve tumour detection and localization because it offers excellent soft tissue contrast between malignant and non-malignant tissues. It also provides a quantitative biomarker; the apparent diffusion coefficient (ADC) can be derived from D...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.03.010

    authors: Bollineni VR,Kramer G,Liu Y,Melidis C,deSouza NM

    更新日期:2015-06-01 00:00:00

  • Cardiotoxicity associated with radiotherapy in breast cancer: A question-based review with current literatures.

    abstract::Radiotherapy is an indispensable unit of multidisciplinary treatment of breast cancer. Although the application of modern techniques has led to a significantly reduction in radiation-induced heart disease, it is still recognized as the leading causes of morbidity and mortality among breast cancer survivors. With the g...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.03.008

    authors: Zhu Q,Kirova YM,Cao L,Arsene-Henry A,Chen J

    更新日期:2018-07-01 00:00:00

  • Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

    abstract:BACKGROUND:Treatment of relapsed hematological malignancies after an allogeneic peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) from the stem cell donor is an attractive clinical option to salvage this group of patients. METHODS:We reviewed the important studies looking at d...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.03.004

    authors: Deol A,Lum LG

    更新日期:2010-11-01 00:00:00

  • Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.

    abstract:PURPOSE:Neoadjuvant chemotherapy followed by surgery (NACT + S) has been compared with definitive chemoradiothherapy (CRT) in randomized clinical trials (RCTs) in stage IB2, IIA and IIB cervical cancer (1994 Figo stage). Our aim was to evaluate efficacy and toxicity of NACT + S and CRT and identify differences in clini...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ctrv.2019.101945

    authors: Marchetti C,Fagotti A,Tombolini V,Scambia G,De Felice F

    更新日期:2020-02-01 00:00:00

  • Pancreatic cancer: current and future treatment strategies.

    abstract::Pancreatic cancer is a disease with a high mortality rate and short survival, as a result of the high incidence of metastatic disease at diagnosis, the fulminant clinical course and the lack of successful therapeutic strategies. The administration of chemotherapeutic agents for the treatment of advanced disease has fa...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.02.005

    authors: Pliarchopoulou K,Pectasides D

    更新日期:2009-08-01 00:00:00

  • An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

    abstract::Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.03.001

    authors: Pasello G,Ceresoli GL,Favaretto A

    更新日期:2013-02-01 00:00:00

  • Preoperative chemotherapy for non-small cell lung cancer.

    abstract::Surgery has been considered the standard of care in patients with early-stage non-small cell lung cancer (NSCLC), as well as in some cases of stage III, for a long time. Poor survival after complete resection has led to the search for new therapeutic strategies such as combining anticancer treatments. However, at the ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2001.0218

    authors: Depierre A,Westeel V,Jacoulet P

    更新日期:2001-04-01 00:00:00

  • Low dose cyclophosphamide: Mechanisms of T cell modulation.

    abstract::Cyclophosphamide is considered one of the most successful chemotherapy drugs and is listed on the World Health Organisations List of Essential Medicines. Since its initial synthesis in 1958, it has been widely used to treat a range of cancers but its use has been declining due to the advent of platinum based and other...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.11.005

    authors: Madondo MT,Quinn M,Plebanski M

    更新日期:2016-01-01 00:00:00

  • Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.

    abstract::Neoadjuvant chemotherapy (NAC) for breast cancer is evolving and subsequent adjuvant systemic treatment is mainly based on the presence of the Estrogen (ER) receptor, Progesterone (PR) receptor and Human Epidermal growth factor Receptor 2 (HER2) status on the core needle biopsy prior to treatment. It is not well known...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.11.006

    authors: van de Ven S,Smit VT,Dekker TJ,Nortier JW,Kroep JR

    更新日期:2011-10-01 00:00:00

  • Adjuvant immunotherapy for non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) is the biggest cancer killer in the United States and worldwide. In 2011, there are estimated to be 221,130 new cases of lung cancer in the United States. Over a million people will die of lung cancer worldwide this year alone. When possible, surgery to remove the tumor is the best t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.11.008

    authors: Tucker ZC,Laguna BA,Moon E,Singhal S

    更新日期:2012-10-01 00:00:00

  • Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.

    abstract:BACKGROUND:The colony-stimulating factors (CSFs) are widely utilized to prevent neutropenic complications in both adults and children, but randomized controlled trials in the pediatric setting have reported varied results. A systematic review of the literature and meta-analysis were conducted to definitively assess the...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2006.03.002

    authors: Wittman B,Horan J,Lyman GH

    更新日期:2006-06-01 00:00:00

  • RAF signaling in neuroendocrine neoplasms: from bench to bedside.

    abstract::Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.06.009

    authors: Fazio N,Abdel-Rahman O,Spada F,Galdy S,De Dosso S,Capdevila J,Scarpa A

    更新日期:2014-09-01 00:00:00

  • Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

    abstract::Whereas first-line chemotherapy (CT) with single-agent gemcitabine or gemcitabine-based combinations provides a proven benefit in patients with locally advanced or metastatic pancreatic cancer (PC), the role of salvage CT after gemcitabine-failure is not well-established and to date no regimen has emerged as preferred...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.08.012

    authors: Custodio A,Puente J,Sastre J,Díaz-Rubio E

    更新日期:2009-12-01 00:00:00

  • Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.

    abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(93)90004-b

    authors: Bonneterre J,Mercier M

    更新日期:1993-04-01 00:00:00

  • Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.

    abstract::Lung cancer represents the most common cause of brain dissemination. Oncogene-addicted (EGFR- and ALK-positive) non-small cell lung cancers (NSCLCs) are characterized by a unique metastatic neurotropism resulting in a particularly high incidence of brain metastases. The goal of optimal brain metastases management is t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.10.011

    authors: Wrona A,Dziadziuszko R,Jassem J

    更新日期:2018-12-01 00:00:00

  • Modulation of response to cancer chemotherapeutic agents by diet constituents: is the available evidence sufficiently robust for rational advice for patients?

    abstract:BACKGROUND:Patients who are diagnosed with cancer want advice on how they may alter their diet or which diet supplements they should take to augment chemotherapy. METHODS:We conducted a review of the literature mostly from the last 15 years on the interaction between dietary constituents and antineoplastic therapy in ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.12.004

    authors: D'Incalci M,Steward WP,Gescher AJ

    更新日期:2007-05-01 00:00:00

  • Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.

    abstract::Despite the initially high response rate to standard front-line debulking surgery followed by platinum-based chemotherapy, the relapse rate in ovarian cancer is high and many patients will recur within 6 months of completing platinum based treatment. These patients may still require further chemotherapy despite being ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.04.004

    authors: Pinato DJ,Graham J,Gabra H,Sharma R

    更新日期:2013-04-01 00:00:00

  • Rectal and colon cancer: Not just a different anatomic site.

    abstract::Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.06.007

    authors: Tamas K,Walenkamp AM,de Vries EG,van Vugt MA,Beets-Tan RG,van Etten B,de Groot DJ,Hospers GA

    更新日期:2015-09-01 00:00:00

  • Arsenical-based cancer drugs.

    abstract::Arsenic is a semi-metal or metalloid with two biologically important oxidation states, As(III) and As(V). As(III), in particular, reacts with closely spaced protein thiols, forming stable cyclic dithioarsinite complexes in which both sulfur atoms are bound to arsenic. It is this reaction that is mostly responsible for...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.05.001

    authors: Dilda PJ,Hogg PJ

    更新日期:2007-10-01 00:00:00

  • Prevention of chemotherapy and radiation toxicity with glutamine.

    abstract:GOALS OF THE WORK:Malignancy produces a state of physiologic stress that is characterized by a relative deficiency of glutamine, a condition that is further exacerbated by the effects of cancer treatment. Glutamine deficiency may impact on normal tissue tolerance to antitumor treatment, and may lead to dose reductions ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00133-6

    authors: Savarese DM,Savy G,Vahdat L,Wischmeyer PE,Corey B

    更新日期:2003-12-01 00:00:00